Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.
D,L-4-(3,4-dichlorobenzoylamino)-5-(N-3-methoxypropyl-pentylami no)-5- oxopentanoic acid (CR 1505; loxiglumide) is a newly developed analog of proglumide. We examined the inhibitory effects of loxiglumide on pancreatic exocrine function in the isolated pancreatic acini and the isolated perfused pancreata of rats. Loxiglumide inhibited cholecystokinin octapeptide (CCK-8)-stimulated amylase release and, similarly, binding of [125I]CCK-8 to isolated rat pancreatic acini. Loxiglumide was about 3000 times more potent than the reference substance proglumide, but was about 1000 times less potent than L-364,718, another new CCK antagonist having benzodiazepine ring, in inhibiting CCK-8-stimulated amylase release. The inhibitory effect of loxiglumide displayed competitive kinetics and was specific for CCK in that the effects of other receptor secretagogues or agents bypassing receptors were not altered. The inhibitory effect of loxiglumide was fully reversible in isolated acini. However, the pancreata perfused with 10 microM loxiglumide for 20 min did not respond to CCK-8 for more than 20 min even after the removal of loxiglumide infusion. In contrast, an immediate increase in pancreatic exocrine secretion was observed after proglumide removal. Loxiglumide appeared to be bound to the receptors on acinar cells in a slowly dissociating state. These results indicate that loxiglumide acts as a potent, competitive, and specific CCK antagonist on the exocrine pancreas and, because of its prolonged inhibitory action, may be useful as a therapeutic agent in pancreatic disease.
Otsuki
M
M
Second Department of Internal Medicine, Kobe University School of Medicine, Japan.
Fujii
M
M
Nakamura
T
T
Okabayashi
Y
Y
Tani
S
S
Fujisawa
T
T
Koide
M
M
Baba
S
S
D000681:Amylases / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D004305:Dose-Response Relationship, Drug; D005973:Glutamine / Q000031:analogs & derivatives*; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism; D011377:Proglumide / Q000031:analogs & derivatives* / Q000494:pharmacology; D051381:Rats; D011949:Receptors, Cholecystokinin / Q000378:metabolism; D012844:Sincalide / Q000378:metabolism / Q000494:pharmacology
D011949:Receptors, Cholecystokinin; D005973:Glutamine; C053737:loxiglumide; D002766:Cholecystokinin; D000681:Amylases; D011377:Proglumide; D012844:Sincalide